Evogene (EVGN) Liabilities and Shareholders Equity (2016 - 2026)
Evogene (EVGN) posted Liabilities and Shareholders Equity of $17948.0 for Q1 2026, down 99.91% sequentially from $20.0 million in Q4 2025, and down 99.95% YoY from $34.3 million in Q1 2025.
Evogene (EVGN) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
Evogene has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $17948.0 in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 99.95% year-over-year to $17948.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.1 million (down 30.45% YoY) and the FY2025 annual result came in at $20.0 million, down 49.71% from the prior year.
- Liabilities and Shareholders Equity slipped to $17948.0 in Q1 2026 per EVGN's latest filing, from $20.0 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $56.7 million in Q2 2022 and troughed at $17948.0 in Q1 2026.
- A 5-year average of $37.5 million and a median of $39.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity dropped 5.86% in 2023, then plunged 99.95% in 2026.
- Over 5 years, Liabilities and Shareholders Equity stood at $56.1 million in 2022, then fell by 8.95% to $51.1 million in 2023, then fell by 21.99% to $39.9 million in 2024, then plunged by 49.71% to $20.0 million in 2025, then plunged by 99.91% to $17948.0 in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $17948.0, $20.0 million, and $26.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 17,948.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,948.00 |
| Dec 31, 2025 | 20.05 Mn |
| Sep 30, 2025 | 26.09 Mn |
| Jun 30, 2025 | 33.93 Mn |
| Mar 31, 2025 | 34.30 Mn |
| Dec 31, 2024 | 39.86 Mn |
| Jun 30, 2024 | 40.97 Mn |
| Dec 31, 2023 | 51.10 Mn |
| Jun 30, 2023 | 53.34 Mn |
| Dec 31, 2022 | 56.13 Mn |
| Jun 30, 2022 | 56.66 Mn |
| Dec 31, 2021 | 76.30 Mn |
| Jun 30, 2021 | 87.54 Mn |
| Dec 31, 2020 | 71.92 Mn |
| Jun 30, 2020 | 61.11 Mn |
| Dec 31, 2019 | 71.36 Mn |
| Dec 31, 2018 | 58.69 Mn |
| Dec 31, 2017 | 77.60 Mn |
| Dec 31, 2016 | 95.99 Mn |